Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
This data becomes invaluable when making titration decisions with your healthcare provider
This gradual approach gives your digestive system time to adjust, lowering nausea and other gastrointestinal effects that some patients experience early in treatment
Patients often notice a reduced appetite within the first few weeks, making it easier to follow healthier eating patterns without feeling deprived
Benefits (Research Focus) Triple receptor agonism studied for simultaneous activation of GLP-1, GIP, and glucagon receptors Body composition research investigated for fat-mass and lean-mass partitioning in DIO rodent models Glycemic endpoints examined for fasting glucose and HbA1c parameters in T2D research models Energy expenditure explored for glucagon-mediated thermogenic effects unique among incretin analogs Long-acting profile C20 fatty diacid albumin-binding chemistry for extended half-life research What Researchers Look At Receptor binding affinity and selectivity across GLP-1R / GIPR / GCGR cAMP activation curves in cell lines expressing each receptor subtype Food intake, body weight, and adipose-tissue change in DIO rodent models Hepatic steatosis, ALT/AST, and liver fat fraction endpoints Comparative pharmacology versus semaglutide, tirzepatide, and other incretin analogs Quick Specs Form: Lyophilized white powder Net Peptide Content: 10 mg per vial Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound: Retatrutide Synonyms: LY3437943
Serum testosterone concentrations predict development of hyperglycaemia in population studies (OReilly et al., 2019)
